证券代码：688399 证券简称：硕世生物 公告编号：2025-046 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第 三季度的经营成果及财务指标的具体情况与投资者进行互动交流和 沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 江苏硕世生物科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 13 日（星期四）至 11 月 19 日（星期三） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 sssw@s-sbio.com 进行提问。公司将在说明会上对投资者普 遍关注的问题进行回答。 江苏硕世生物科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 25 日发布公司 2025 年第三季度报告，为便于广大投资者更 全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计 划于 2025 年 11 月 20 日（ ...

证券代码：688399 证券简称：硕世生物 公告编号：2025-044 江苏硕世生物科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 11 日 （二） 股东大会召开的地点：江苏省泰州市药城大道 837 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 63 | | --- | --- | | 普通股股东人数 | 63 | | 2、出席会议的股东所持有的表决权数量 | 34,754,254 | | 普通股股东所持有表决权数量 | 34,754,254 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 41.4373 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 41.4373 | （四） 表 ...

上海市通力律师事务所关于江苏硕世生物科技股份有限公司 2025 年第二次临时股东大会的法律意见书 致:江苏硕世生物科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受江苏硕世生物科技股份有限公司 (以下简称"公司")的委托,指派本所茹秋乐律师、韩宇律师(以下简称"本所律师") 根据《中华人民共和国公司法》《中华人民共和国证券法》等法律法规和规范性文件(以 下统称"法律法规")及《江苏硕世生物科技股份有限公司章程》(以下简称"公司章 程")的规定就公司 2025年第二次临时股东大会(以下简称"本次股东大会")相关 事宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以 了核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中 的所有签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、 完整和有效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会 人员资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表 意见,并不对本次股东大会所审 ...

Group 1 - The core viewpoint of the news is that Shuoshi Biotechnology has shown significant stock price performance and trading activity, with a year-to-date increase of 89.73% and a market capitalization of 6.525 billion yuan [1] - As of November 7, the stock price reached 77.80 yuan per share, with a trading volume of 35.4253 million yuan and a turnover rate of 0.55% [1] - The company has experienced net outflows of main funds amounting to 629,500 yuan, while large orders showed a mixed trend with total buy orders of 5.3918 million yuan and sell orders of 6.1871 million yuan [1] Group 2 - Shuoshi Biotechnology, established on April 12, 2010, specializes in the research, production, and sales of in vitro diagnostic products, with a revenue composition of 85.89% from testing reagents [2] - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics, and is involved in various concept sectors including small-cap stocks and high dividends [2] - For the period from January to September 2025, the company reported a revenue of 258 million yuan, a year-on-year decrease of 3.95%, and a net profit attributable to the parent company of 3.1517 million yuan, down 88.38% year-on-year [2] Group 3 - Since its A-share listing, Shuoshi Biotechnology has distributed a total of 1.37 billion yuan in dividends, with 285 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders decreased by 0.94% to 7,620, while the average circulating shares per person increased by 0.94% to 11,006 shares [2][3]

Core Viewpoint - The stock price of Shuoshi Biotechnology has experienced fluctuations, with a year-to-date increase of 85.86% but a recent decline of 2.86% over the past five trading days [2] Group 1: Stock Performance - As of November 4, Shuoshi Biotechnology's stock price was 76.21 CNY per share, with a market capitalization of 6.392 billion CNY [1] - The stock has seen a year-to-date increase of 85.86%, a 2.86% decline in the last five trading days, a 19.26% increase over the last 20 days, and a 36.60% increase over the last 60 days [2] - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 19.7845 million CNY on February 17 [2] Group 2: Financial Performance - For the period from January to September 2025, Shuoshi Biotechnology reported revenue of 258 million CNY, a year-on-year decrease of 3.95%, and a net profit attributable to shareholders of 3.1517 million CNY, down 88.38% year-on-year [3] - The company has distributed a total of 1.37 billion CNY in dividends since its A-share listing, with 285 million CNY distributed over the past three years [4] Group 3: Shareholder Information - As of October 20, 2025, the number of shareholders for Shuoshi Biotechnology was 7,620, a decrease of 0.94% from the previous period, while the average circulating shares per person increased by 0.94% to 11,006 shares [3] - As of September 30, 2025, one of the top ten circulating shareholders, 华夏行业景气混合A (003567), has exited the list [4] Group 4: Business Overview - Shuoshi Biotechnology, established on April 12, 2010, and listed on December 5, 2019, specializes in the research, production, and sales of in vitro diagnostic products, including diagnostic reagents and supporting testing instruments [2] - The company's main revenue sources are diagnostic reagents (85.89%), purchased instruments and materials (7.19%), testing instruments (3.84%), testing services (2.24%), and others (0.84%) [2] - The company is classified under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics [2]

Core Viewpoint - The stock price of Shuoshi Biotechnology has experienced significant fluctuations, with a year-to-date increase of 84.68%, but recent trading shows a decline of 2.01% on October 30, 2023, indicating potential volatility in investor sentiment [1][2]. Company Overview - Shuoshi Biotechnology, established on April 12, 2010, and listed on December 5, 2019, is located in Taizhou, Jiangsu Province. The company specializes in the research, production, and sales of in vitro diagnostic reagents and related testing instruments [2]. - The main revenue sources for the company include diagnostic reagents (85.89%), purchased instruments and materials (7.19%), testing instruments (3.84%), testing services (2.24%), and others (0.84%) [2]. Financial Performance - For the period from January to September 2025, Shuoshi Biotechnology reported a revenue of 258 million yuan, reflecting a year-on-year decrease of 3.95%. The net profit attributable to the parent company was 3.15 million yuan, down 88.38% year-on-year [3]. - The company has distributed a total of 1.37 billion yuan in dividends since its A-share listing, with 285 million yuan distributed over the past three years [4]. Shareholder and Market Activity - As of October 20, 2023, the number of shareholders for Shuoshi Biotechnology was 7,620, a decrease of 0.94% from the previous period. The average circulating shares per person increased by 0.94% to 11,006 shares [3]. - The company has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 19.78 million yuan on February 17, 2023, accounting for 26.20% of the total trading volume [2]. Market Sentiment and Trading Activity - On October 30, 2023, the stock price was reported at 75.73 yuan per share, with a trading volume of 45.34 million yuan and a turnover rate of 0.71%. The total market capitalization stood at 6.352 billion yuan [1]. - The net outflow of main funds was 3.40 million yuan, with large orders showing a buy of 12.05 million yuan (26.58%) and a sell of 15.78 million yuan (34.80%) [1].

江苏硕世生物科技股份有限公司 2025 年第二次临时股东大会会议材料 证券简称：硕世生物 证券代码：688399 江苏硕世生物科技股份有限公司 2025 年第二次临时股东大会 会议材料 2025 年 11 月 11 日 江苏硕世生物科技股份有限公司 2025 年第二次临时股东大会会议材料 江苏硕世生物科技股份有限公司 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则》以及《江苏硕世生物科技股份有限公司章程》《江苏硕世 生物科技股份有限公司股东大会议事规则》等相关规定，特制定 2025 年第二次 临时股东大会须知。 一、为保证本次大会的严肃性和正常秩序，切实维护与会股东（或股东代理 人）的合法权益，除出席会议的股东（或股东代理人）、公司董事、监事、高级 管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他无关人员进 入会场。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示证券账户卡、身份证明文件或营业执照复印件（ ...

Core Points - The mid-term dividends from 20 companies, including Beijing-Shanghai High-Speed Railway Co., Ltd., Guotai Junan Securities Co., Ltd., and State Power Development Co., Ltd., will exceed 9 billion yuan from October 27 to October 31 [1] - As of October 24, 320 companies in the Shanghai market have distributed over 278 billion yuan in mid-term dividends, with an additional 90 companies expected to distribute over 280 billion yuan [1][2] - The total mid-term dividend amount for 414 companies has reached over 560 billion yuan, setting a historical high [1] Company-Specific Information - Major dividend payers include China Mobile and China Telecom, with cash distributions of 54.1 billion yuan and 16.6 billion yuan, respectively, while the "Big Three" oil companies have collectively distributed approximately 82.5 billion yuan [2] - Companies like Xiamen Gibit Network Technology Co., Ltd. and Jiangsu Shuoshi Biotechnology Co., Ltd. have reported per-share dividends exceeding 2 yuan, with Gibit reaching 6.6 yuan per share [2] Dividend Yield Insights - The dividend yield for 290 companies in the Shanghai market exceeds 3%, with 81 companies yielding over 5% [3] - Among the 320 companies that have implemented mid-term dividends, the average yield is 2.53%, with 102 companies exceeding 3% and 40 companies surpassing 5% [3]

Group 1 - The company has decided to change its registered capital and abolish the supervisory board, transferring its powers to the audit committee under the board of directors, which is in compliance with relevant laws and regulations [1][3] - The supervisory board unanimously agreed to the proposal, which aims to improve the corporate governance structure and better meet the company's operational needs [1][2] - The specific details of the changes were disclosed on the Shanghai Stock Exchange website [1] Group 2 - The company held its 13th meeting of the third board of directors on October 23, 2025, where it approved the appointment of Hu Yuanyuan as a member of the Strategy and ESG Committee [4][6] - The composition of the Strategy and ESG Committee after the appointment includes Fang Yongsheng (Chairman), Wang Guoqiang, Gao Guangxia, and Hu Yuanyuan [4] Group 3 - The company has scheduled its second extraordinary general meeting of shareholders for November 11, 2025, at 13:30 [7][8] - The meeting will be held at the company's conference room located at 837 Yaowang Avenue, Taizhou, Jiangsu Province [8] Group 4 - The company plans to conduct charitable donations in 2025, with a total amount not exceeding RMB 1.5 million, aimed at fulfilling its social responsibilities [27][28] - The donations will include cash and physical assets, and the management is authorized to handle all related matters [28][29] Group 5 - The company appointed Tu Xiaobao as the vice president, effective from the date of the board's approval until the end of the current board's term [31][32] - Tu Xiaobao has extensive experience in the company and meets the qualifications required for the position [31][33]

Core Points - The company has announced changes in its registered capital and governance structure, including the cancellation of the supervisory board and amendments to its articles of association [7][8] - The company completed a share buyback program, resulting in a reduction of registered capital due to the cancellation of 1.949918 million shares [7] - Following a capital reserve conversion, the company's total share capital increased from 56.670082 million shares to 83.871721 million shares, with corresponding registered capital rising from RMB 56.670082 million to RMB 83.871721 million [7] Financial Data - The financial statements for the third quarter are unaudited, and the company has confirmed the accuracy and completeness of the financial information presented [3][4] - The company has not reported any non-recurring gains or losses for the current period [4] - The company has not experienced significant changes in major accounting data or financial indicators [5] Shareholder Information - The company has provided details on the total number of shareholders and the status of major shareholders, although specific figures are not disclosed in the announcement [6] Governance Changes - The company will no longer have a supervisory board, with the audit committee of the board taking over its responsibilities [8] - The company plans to comprehensively revise its articles of association and related governance documents to reflect these changes [8]